Salvianolic acid A

DB15246InvestigationalSmall molecule

Salvianolic acid A is under investigation in clinical trial NCT03908242 (Phase I Study of Continuous Administration of Salvianolic Acid A Tablet).

Mechanism: Pharmacologically active on Matrix metalloproteinase-9 and Phosphatidylinositol 3-kinase
Curator reviewed
Formula / weight: C₂₆H₂₂O₁₀ · 494.452 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyYMGFTDKNIWPMGF-UCPJVGPRSA-NSMILESOC(=O)[C@@H](CC1=CC(O)=C(O)C=C1)OC(=O)\C=C\C1=C(/C=C/C2=CC(O)=C(O)C=C2)C(O)=C(O)C=C1

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Salvianolic acid A, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.